Thursday, Mar 26, 2015
South San Francisco, Calif. -- March 26, 2015 --
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon. "This investment in our sterile production operations will result in the addition of up to 100 new skilled manufacturing jobs in the greater Portland area over the next five years, potentially bringing the total number of Genentech jobs in Oregon to over 500," said Larry Sanders, General Manager and Vice President, Hillsboro Technical Operations.
"This announcement is another indicator that this is an exciting time in Oregon’s history," said Governor Kate Brown. "Genentech’s investment in its Hillsboro campus and Oregon’s robust workforce underscore that Oregon is a great place for all businesses to build their future and for the biotech sector to grow."
Genentech opened operations in Hillsboro in April 2010. The site is home to a state-of-the-art fill/finish facility and warehousing and distribution center. Genentech's product pipeline is among the strongest in the biotechnology and pharmaceutical industries, and demand for its marketed products continues to grow. The expansion of operations at the Hillsboro site is part of the company’s strategy to increase manufacturing capacity to meet that demand.
"Genentech’s plan to expand its Hillsboro facility represents an important milestone in the industry’s growth trajectory in Oregon. Combined with other recent achievements like the historic Knight Cancer Challenge, Oregon is positioned to significantly expand our life sciences manufacturing footprint," said Dennis McNannay, Executive Director of the Oregon Bioscience Association.
About Biologics Manufacturing
Genentech was the first biotechnology company to scale up protein manufacturing successfully from the small quantities used for research to the much larger quantities needed for clinical trials and marketing. Today Genentech and Roche are a world leader in biologics manufacturing, with more FDA-approved manufacturing capacity for the production of biotech medicines than any other company. Over the last two decades, Genentech has built world-class production facilities, developed expertise in commercially viable manufacturing processes, and also attracted and retained key personnel with experience in all aspects of large-scale biologics manufacturing. Genentech's manufacturing expertise, capacity and portfolio of capacity enhancement projects position the company well to meet the internally forecasted demands for our products. Our dedication to world-class biologics manufacturing and our careful planning for the future will assist us in continuing to deliver innovative therapies to patients with serious and life-threatening diseases.
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.